BMS Presents Robust Mavacamten Results in HCM Ahead of FDA Decision

Over the weekend, Bristol Myers Squibb announced results from an extended study to evaluate the long-term effects of taking cardiovascular drug mavacamten. The EXPLORER-LTE was named after the clinical trial from which it stems: EXPLORER-HCM, a Phase III trial that concluded in 2020. The results showed positive outcomes for those who extended their participation for several additional months. This positive outcome was foreshadowed by the success seen in the original EXPLORER-HCM trial.